Role of α1-acid glycoprotein in therapeutic antifibrotic effects of imatinib with macrolides in mice

American Journal of Respiratory and Critical Care Medicine

Volumn 176, Issue 12, 2007, Pages 1243-1250

  Azuma, Momoyo ^a   Nishioka, Yasuhiko ^a   Aono, Yoshinori ^a   Inayama, Mami ^a   Makino, Hideki ^a   Kishi, Jun ^a   Shono, Masayuki ^a   Kinoshita, Katsuhiro ^a   Uehara, Hisanori ^a   Ogushi, Fumitaka ^b   Izumi, Keisuke ^a   Sone, Saburo ^a  

^a UNIVERSITY OF TOKUSHIMA   (Japan)

^b National Hospital Organization   (Japan)

Author keywords

Clarithromycin; Erythromycin; Fibroblast; Platelet derived growth factor

Indexed keywords

BLEOMYCIN; CLARITHROMYCIN; ERYTHROMYCIN; IMATINIB; OROSOMUCOID; MACROLIDE; PIPERAZINE DERIVATIVE; PROTEIN KINASE INHIBITOR; PYRIMIDINE DERIVATIVE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG EFFECT; DRUG INHIBITION; FEMALE; FIBROBLAST; FIBROGENESIS; GROWTH INHIBITION; IN VITRO STUDY; IN VIVO STUDY; LUNG FIBROSIS; MITOGENESIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; TREATMENT FAILURE; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ADMINISTRATION; DRUG COMBINATION; METABOLISM; PHYSIOLOGY;

ANIMALS; CELLS, CULTURED; CLARITHROMYCIN; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; ERYTHROMYCIN; FEMALE; FIBROBLASTS; MACROLIDES; MICE; OROSOMUCOID; PIPERAZINES; PROTEIN KINASE INHIBITORS; PULMONARY FIBROSIS; PYRIMIDINES;

EID: 37149052105     PISSN: 1073449X     EISSN: 15354970     Source Type: Journal    
DOI: 10.1164/rccm.200702-178OC     Document Type: Article

References (40)

1. Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med 2001;345:517-525.
2. Selman M, King TE Jr, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136-151.
3. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment [international consensus statement]. Am J Respir Crit Care Med 2000;161:646-664.
4. Collard HR, King TE Jr. Demystifying idiopathic interstitial pneumonia. Arch Intern Med 2003;163:17-29.
5. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmermann J, Lydon NB. Effects of a selective inhibitor of the abl tyrosine kinase on the growth of bcr-abl positive cells. Nat Med 1996;2:561-566.
6. Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001;344:1031-1037.
7. Druker BJ, Sawyers CL, Kantarjian H, Resta DJ, Reese SF, Ford JM, Capdeville R, Talpaz M. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001;344:1038-1042.
8. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, Heinrich MC, Tuveson DA, Singer S, Janicek M, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002;347:472-480.
9. van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, Martens M, Webb A, Sciot R, Van Glabbeke M, et al.; European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001;358:1421-1423.
10. Apperley JF, Gardembas M, Melo JV, Russell-Jones R, Bain BJ, Baxter EJ, Chase A, Chessells JM, Colombat M, Dearden CE, et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. N Engl J Med 2002;347:481-487.
11. Cools J, DeAngelo DJ, Gotlib J, Stover EH, Legare RD, Cortes J, Kutok J, Clark J, Galinsky I, Griffin JD, et al. A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome. N Engl J Med 2003;348:1201-1214.
12. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-1316.
13. Li X, Eriksson U. Novel PDGF family members: PDGF-C and PDGF-D. Cytokine Growth Factor Rev 2003;14:91-98.
14. Daniels CE, Wilkes MC, Edens M, Kottom TJ, Murphy SJ, Limper AH, Leof EB. Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycin-mediated lung fibrosis. J Clin Invest 2004;114:1308-1316.
15. Aono Y, Nishioka Y, Inayama Y, Ugai M, Kishi J, Uehara H, Izumi K, Sone S. Imatinib as a novel antifibrotic agent in bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2005;171:1279-1285.
16. Abdollahi A, Li M, Ping G, Plathow C, Domhan S, Kiessling F, Lee LB, McMahon G, Grone H-J, Lipson KE, et al. Inhibition of platelet-derived growth factor signaling attenuates pulmonary fibrosis. J Exp Med 2005;201:925-935.
17. Gilbert RE. Kelly DJ, McKay T, Chadban S, Hill PA, Cooper ME, Atkins RC, Nikolic-Paterson DJ. PDGF signal transduction inhibition ameliorates experimental mesangial proliferative glomerulonephritis. Kidney Int 2001;59:1324-1332.
18. Wang S, Wilkes MC, Leof EB, Hirschberg R. Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo. FASEB J 2005;19:1-11.
19. Yoshiji H, Noguchi R, Kuriyama S, Ikenaka Y, Yoshii J, Yanase K, Namisaki T, Kitade M, Masaki T, Fukui H. Imatinib mesylate (STI571) attenuates liver fibrosis development in rats. Am J Physiol Gastrointest Liver Physiol 2005;288:G907-G913.
20. Neef M, Ledermann M, Saegesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J. Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 2006;44:167-175.
21. Bouros D, Antoniou KM. Current and future therapeutic approaches in idiopathic pulmonary fibrosis. Eur Respir J 2005;26:693-702.
22. + leukemic cells to the abl inhibitor STI571. J Natl Cancer Inst 2000;92:1641-1650.
23. 1 Acid glycoprotein binds to imatinib (STI571) and substantially alters its pharmacokinetics in chronic myeloid leukemia patients. Clin Cancer Res 2003;9:625-632.
24. 1-acid glycoprotein [abstract]. Am J Respir Crit Care Med 2005;2:A636.
25. Nishioka Y, Yano S, Fujiki F, Mukaida N, Matsushima K, Tsuruo T, Sone S. Combined therapy of multidrug-resistant human lung cancer with anti-P-glycoprotein antibody and monocyte chemoattractant protein-1 gene transduction:the possibility of immunological overcoming of multidrug resistance. Int J Cancer 1997;71:170-177.
26. Harrison JH, Lazo JS. High dose continuous infusion of bleomycin in mice: a new model for drug-induced pulmonary fibrosis. J Pharmacol Exp Ther 1987;243:1185-1194.
27. Inayama M, Nishioka Y, Azuma M, Muto S, Aono Y, Makino H, Tani K, Uehara H, Izumi K, Itai A, et al. A novel IκB kinase-β inhibitor ameliorates bleomycin-induced pulmonary fibrosis in mice. Am J Respir Crit Care Med 2006;173:1016-1022.
28. Ashcroft T, Simpson JM, Timbrell V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale. J Clin Pathol 1988;41:467-470.
29. Phan SH, Varani J, Smith D. Rat lung fibroblast collagen metabolism in bleomycin-induced pulmonary fibrosis. J Clin Invest 1985;76:241-247.
30. Ishikawa Y, Yuan Z, Inoue N, Skowronski MT, Nakae Y, Shono M, Cho G, Yasui M, Agre P, Nielsen S. Identification of AQP5 in lipid rafts and its translocation to apical membranes by activation of M3 mAChRs in interlobular ducts of rat parotid gland. Am J Physiol Cell Physiol 2005;289:1303-1311.
31. Kuroha M, Son DS, Shimoda M. Effects of altered plasma α1 acid glycoprotein levels on pharmacokinetics of some basic antibiotics in pigs: simulation analysis. J Vet Pharmacol Ther 2001;24:423-431.
32. Li Y, Azuma A, Takahashi S, Usuki J, Matsuda K, Aoyama A, Kudoh S. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: role in preventing lung injury and fibrosis in bleomycin-challenged mice. Chest 2002;122:2137-2145.
33. Fournier T, Medjoubi-N N, Porquet D. Alpha-1-acid glycoprotein. Biochim Biophys Acta 2000;1482:157-171.
34. Fernandes PB, Hardy DJ, McDaniel D, Hanson CW, Swanson RN. In vitro and in vivo activities of clarithromycin against Mycobacterium avium. Antimicrob Agents Chemother 1989;33:1531-1534.
35. Conte JE Jr, Golden JA, Duncan S, McKenna E, Zurlinden E. Intrapulmonary pharmacokinetics of clarithromycin and of erythromycin. Antimicrob Agents Chemother 1995;39:334-338.
36. Kawashima M, Tatsunami J, Fukuno Y, Nagata M, Tominaga M, Hayashi S. Inhibitory effects of 14-membered ring macrolides antibiotics on bleomycin-induced acute lung injury. Lung 2002;180:73-89.
37. Desaki M, Takizawa H, Ohtoshi T, Kasama T, Kobayashi K, Sunazuka T, Omura S, Yamamoto K, Ito K. Erythromycin suppresses nuclear factor-κB and activator protein-1 activation in human bronchial epithelial cells. Biochem Biophys Res Commun 2000;267:124-128.
38. Crestani B, Rolland C, Lardeux B, Fournier T, Bernuau D, Pous C, Vissuzaine C, Li L, Aubier M. Inducible expression of the α1-acid glycoprotein by rat and human type II alveolar epithelial cells. J Immunol 1998;160:4596-4605.
39. Fournier T, Bouach N, Delafosse C, Crestani B, Aubier M. Inducible expression and regulation of the alpha 1-acid glycoprotein gene by alveolar macrophages: prostaglandin E2 and cyclic AMP act as new positive stimuli. J Immunol 1999;163:2883-2890.
40. Van Den Heuvel MM, Poland DC, De Graaff CS, Hoefsmit EC, Postmus PE, Beelen RH, Van Dijk W. The degree of branching of the glycans of α1-acid glycoprotein in asthma: a correlation with lung function and inflammatory parameters. Am J Respir Crit Care Med 2000;161:1972-1978.